Out Now: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
Following its recent announcement, the AmoyDx® FGFR1-4 NGS Panel (RUO) is now available offering a robust NGS assay for the qualitative detection of mutations (SNVs, InDels) and fusions in FGFR1-4 genes at DNA and RNA levels, respectively. The panel covers the full coding sequences of all four genes and utilizes a hybrid capture technology (ddCAP) for library preparation. Its optimized DNA/cDNA co-library preparation workflow mostly takes place within a single reaction tube, enhancing efficiency and ease of use.
Learn more here.
For further information, please contact us at molpath@zytomed-systems.de
Further topics
S3 guideline for prostate cancer was updated
In May 2024 the S3 guideline "Prostate Cancer" (version 7.0) was updated. For the first time it is recommended to sequence genes involved in homologous recombination repair (HRR), e. g. ATM, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, HDAC2 and PALB2, before initiating a systemic therapy for castration-resistant prostate cancer (mCRPC).
Coming soon: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
